Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Daly James M reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director James M. Daly received 191 shares of common stock as a fully vested equity award under the Director Equity in Lieu of Cash Retainer Program. The shares were valued at $65.37 each on the grant date. After this award, Daly directly holds 388 CYTK common shares.
CYTOKINETICS INC executive Andrew Callos reported an open-market sale of company stock. As EVP and Chief Commercial Officer, he sold 7,449 shares of Common Stock at a price of $66.02 per share. Following this transaction, he directly holds 58,555 shares of CYTOKINETICS INC Common Stock.
Cytokinetics Inc President & CEO Robert I. Blum reported an open-market sale of common stock. He sold 7,500 shares of Cytokinetics common stock at $65.38 per share on April 15, 2026.
After this transaction, Blum directly owns 415,330 shares of Cytokinetics common stock. He also has indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
Andrew Callos reported proposed sales of Common Stock via a Form 144. The notice lists 72,190 shares tied to an exercise of stock options (04/15/2026) and 7,449 shares tied to Restricted Stock Units (03/15/2026). The filing also lists multiple completed 10b5-1 sales in Feb–Mar 2026, including sales of 15,000 shares on 03/05/2026.
Cytokinetics EVP of Research & Development Fady Malik exercised stock options and sold shares on April 7, 2026. He exercised options covering 3,500 shares at $7.80 and 1,000 shares at $10.60 per share, then sold a total of 4,500 common shares in open-market transactions.
The sales involved 3,500 shares at $65.21 and 1,000 shares at $64.75 per share. After these exercise-and-sell transactions, he directly holds 153,902 shares of Cytokinetics common stock. This filing reflects a routine combination of option exercises and partial share sales by a senior executive.
CYTK filing reports an intended sale of 22,000 shares of Common Stock on 04/07/2026 following the exercise of stock options for cash. The filing lists brokerage placement with Morgan Stanley Smith Barney LLC and discloses prior sales by Fady Malik of 12,033 and 2,907 shares on 03/17/2026 and 03/09/2026, respectively, with disclosed gross proceeds.
Insider Robert Blum reported planned and recent disposals of Cytokinetics common stock via Form 144. The filing lists 45,000 Restricted Stock Units to be sold and shows two reported disposals in the past three months: 36,601 shares for $2,274,752.15 and 7,931 shares for $481,570.32. The cover lists an aggregate value of $2,965,950.00 and a figure of 123,162,807 shown alongside the 04/01/2026 date.
Cytokinetics Inc President & CEO Robert I. Blum sold 7,500 shares of Common Stock in an open-market transaction at $66.63 per share. Following the sale, he directly holds 422,830 shares. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
CYTK filing notifies a proposed sale of 3,639 Restricted Stock Units dated 03/06/2026. The filing also lists multiple 10b5-1 dispositions by Andrew Callos between 01/02/2026 and 03/18/2026, including sales of 15,000 shares on 03/05/2026 and other dated transactions with reported proceeds.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 3,639 shares of Common Stock in an open-market transaction at $65.00 per share. The sale occurred on March 31, 2026. After this transaction, he continues to hold 66,004 shares of Cytokinetics Common Stock directly.